Clinical Trial Update: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing JNJ-18038683 for cognition and depressive symptoms in stable bipolar disorder; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• JNJ-18038683

Snippet

Sponsor: Herbert Meltzer | Conditions: Bipolar Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03